SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), a leading provider of continuous glucose monitoring systems for use by people with diabetes at home and by healthcare providers in the hospital, announced today the amendment of its joint development agreement with Animas Corporation to extend outside the U.S. This revised agreement gives Animas exclusive rights to DexCom CGM technology, now and in the future, for integration into Animas insulin pumps outside the U.S. Animas also retains the non-exclusive right to develop and market CGM-enabled ambulatory insulin pumps within the United States.
